Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022011125 - CROSSLINKED HYDROGEL FOR IMMUNE CHECKPOINT BLOCKADE DELIVERY

Publication Number WO/2022/011125
Publication Date 13.01.2022
International Application No. PCT/US2021/040863
International Filing Date 08.07.2021
IPC
A61K 47/60 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Applicants
  • GEORGIA TECH RESEARCH CORPORATION [US]/[US]
  • UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. [US]/[US]
  • GARCIA, Andres J. [US]/[US]
  • CORONEL, Maria M. [US]/[US]
  • SHIRWAN, Haval [US]/[US]
  • YOLCU, Esma S. [US]/[US]
Inventors
  • GARCIA, Andres J.
  • CORONEL, Maria M.
  • SHIRWAN, Haval
  • YOLCU, Esma S.
Agents
  • CUTCHINS, William W.
  • HALL, Miles E.
Priority Data
63/049,18508.07.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) CROSSLINKED HYDROGEL FOR IMMUNE CHECKPOINT BLOCKADE DELIVERY
(FR) HYDROGEL RÉTICULÉ D'ADMINISTRATION DE BLOCAGE DE POINT DE CONTRÔLE IMMUNITAIRE
Abstract
(EN) Disclosed are PD-L1 presenting compositions. The compositions may be used to effect immunomodulation in a variety of contexts. The compositions may be used to decrease rates of transplant rejection, including pancreatic islet cell transplantation. The compositions are useful for the treatment of type 1 diabetes.
(FR) L'invention concerne des compositions présentant PD-L1. Les compositions peuvent être utilisées pour effectuer une immunomodulation dans divers contextes. Les compositions peuvent être utilisées pour diminuer les taux de rejet de greffe, notamment de greffe de cellules de Langerhans pancréatiques. Les compositions sont utiles dans le traitement du diabète de type 1.
Latest bibliographic data on file with the International Bureau